Assessment of antithrombic agents for endoscopic procedure using biopsy forceps
Not Applicable
- Conditions
- patients on anti-thrombotic therapy who need gastrointestinal endoscopy procedure using biopsy forceps.
- Registration Number
- JPRN-UMIN000004937
- Lead Sponsor
- Shinshu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 1500
Inclusion Criteria
Not provided
Exclusion Criteria
1)without agreement 2)PT-INR>3.0 in warfarin taking patients(within 1 Month before procudere) 3)taking dual antiplatelet therapy(both aspirin and thienopyridine delivatives)(patients under discontinuation of thienopyridine delivatives before biopsy procedure can be enrolled). 4)receiving both anticoagulant and antiplatelet therapy(patients with discontinuation of antiplatelet agents or warfarin before biopsy procedure can be enrolled). 5)taking antiplatelet agents other than aspirin or thienopyridine derivatives. 6)within 12months after drug eluting stent placement. 7)taking warfarin for DVT. 8)other serious conditions, pregnency, overt bleeding tendency.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)the prevalence and severity of gastric bleeding during gastric biopsy, and the prevalence of gastric breeding which requires hemostatic therapy. 2)The prevalence and severity of postoperative gastric bleedig after gastric biopsy, and the prevalence of the breeding which requires hemostatic therapy.
- Secondary Outcome Measures
Name Time Method 1)the prevalence and severity of thromboembolic events.